Aktis Oncology officer plans to sell 25,000 shares

The proposed shares are expected to come from stock-option exercises over the next three months, with a sale date listed as September 23, 2026.

Rhea-AI Filing Summary

Aktis Oncology, Inc. officer Akos Czibere reported plans to sell 25,000 common shares, with an aggregate market value of $552,750.00. The notice lists September 23, 2026 as the approximate sale date and names Morgan Stanley Smith Barney LLC as broker. The shares are expected to be received through stock-option exercises over the next three months, with acquisition and payment dates tied to the exercise and sale dates. It also reports that Czibere sold 50,000 common shares on July 8, 2026, with an aggregate market value of $1,388,701.12.

Key Figures

Shares to be sold: 25,000 common shares Aggregate market value: $552,750.00 Shares outstanding: 53,746,670 shares +2 more

5 metrics

Shares to be sold 25,000 common shares Approximate sale date: September 23, 2026

Aggregate market value $552,750.00 For the proposed sale of 25,000 common shares

Shares outstanding 53,746,670 shares Reported in the securities information section

Shares sold during the past three months 50,000 common shares Sale date: July 8, 2026

Aggregate market value of prior sale $1,388,701.12 Sale date: July 8, 2026

Key Terms

Rule 144, stock options

2 terms

Rule 144 regulatory

"the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock options financial

"received upon the exercise of stock options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AKTS shares does officer Akos Czibere plan to sell?

Akos Czibere reported plans to sell 25,000 common shares, with an aggregate market value of $552,750.00. The notice lists September 23, 2026 as the approximate sale date.

Where will the shares in Akos Czibere's planned AKTS sale come from?

The shares are expected to be received through stock-option exercises over the next three months. The stated acquisition and payment dates are the dates of exercise and sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/23/2026 - 04:21 PM Accepted by SEC EDGAR 09/23/2026 - 04:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002049427
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AKTIS ONCOLOGY INC
SEC File Number	001-43047
Address of Issuer	17 Drydock Avenue, Suite 17-401 Boston MASSACHUSETTS 02210
Phone	6174614023
Name of Person for Whose Account the Securities are To Be Sold	Akos Czibere
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	552750.00	53746670	09/23/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/23/2026	Exercise of Stock Options	Issuer			25000	09/23/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AKOS CZIBERE 17 Drydock Avenue, Suite 17-401 Boston MA 02210	Common	07/08/2026	50000	1388701.12

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	09/23/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Akos Czibere
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)